血液灌流对新冠肺炎呼吸衰竭患者治疗结果的影响:一项前瞻性研究

IF 1.1 Q4 IMMUNOLOGY
Effat Rafiee, Samad Ghodrati, Ayoub Pezeshgi, Masumeh Hasanlu, F. Salarpour, Kamyar Mansori, N. Parsamanesh
{"title":"血液灌流对新冠肺炎呼吸衰竭患者治疗结果的影响:一项前瞻性研究","authors":"Effat Rafiee, Samad Ghodrati, Ayoub Pezeshgi, Masumeh Hasanlu, F. Salarpour, Kamyar Mansori, N. Parsamanesh","doi":"10.34172/ipp.2023.38457","DOIUrl":null,"url":null,"abstract":"Introduction: COVID-19 emerged as a global clinical threat following an outbreak in China in late 2019. Objectives: The aim of the current study was to assess the effect of hemoperfusion in COVID-19 patients with respiratory failure. Patients and Methods: In this prospective study, a total of 98 patients over the age of 18 with the positive COVID-19 polymerase chain reaction (PCR) test were investigated. The patients were divided into two groups; a control group consisting of 47 patients who did not receive hemoperfusion, and an exposed group consisting of 51 patients who met the criteria for hemoperfusion. Various parameters including complete blood cell counts, serum bilirubin, creatinine, C-reactive protein (CRP), and interleukin 6 (IL-6) levels were evaluated in all patients. Results: The results of our study revealed a statistically significant difference in intensive care unit (ICU) admission between the two groups. Hospitalization time (19.941±1.75 versus 14.615±1.39, P=0.021) and ICU time (14.98±1.30 versus 9.62±1.15; P=0.003) were significantly higher in patients who received hemoperfusion. Regarding the mortality rate, only 36.7% of the patients survived; however, there was no significant difference observed between the two groups (P=0.34). Conclusion: In conclusion, the findings of our study indicate that hemoperfusion in COVID-19 patients with respiratory failure led to a significant increase in hospital stay and ICU stay compared to those without hemoperfusion. Further research is needed to determine the optimal timing and frequency of hemoperfusion to improve treatment outcomes in COVID-19 patients with respiratory failure.","PeriodicalId":13454,"journal":{"name":"Immunopathologia Persa","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2023-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The effect of hemoperfusion on treatment outcomes in COVID-19 patients with respiratory failure: a prospective study\",\"authors\":\"Effat Rafiee, Samad Ghodrati, Ayoub Pezeshgi, Masumeh Hasanlu, F. Salarpour, Kamyar Mansori, N. Parsamanesh\",\"doi\":\"10.34172/ipp.2023.38457\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: COVID-19 emerged as a global clinical threat following an outbreak in China in late 2019. Objectives: The aim of the current study was to assess the effect of hemoperfusion in COVID-19 patients with respiratory failure. Patients and Methods: In this prospective study, a total of 98 patients over the age of 18 with the positive COVID-19 polymerase chain reaction (PCR) test were investigated. The patients were divided into two groups; a control group consisting of 47 patients who did not receive hemoperfusion, and an exposed group consisting of 51 patients who met the criteria for hemoperfusion. Various parameters including complete blood cell counts, serum bilirubin, creatinine, C-reactive protein (CRP), and interleukin 6 (IL-6) levels were evaluated in all patients. Results: The results of our study revealed a statistically significant difference in intensive care unit (ICU) admission between the two groups. Hospitalization time (19.941±1.75 versus 14.615±1.39, P=0.021) and ICU time (14.98±1.30 versus 9.62±1.15; P=0.003) were significantly higher in patients who received hemoperfusion. Regarding the mortality rate, only 36.7% of the patients survived; however, there was no significant difference observed between the two groups (P=0.34). Conclusion: In conclusion, the findings of our study indicate that hemoperfusion in COVID-19 patients with respiratory failure led to a significant increase in hospital stay and ICU stay compared to those without hemoperfusion. Further research is needed to determine the optimal timing and frequency of hemoperfusion to improve treatment outcomes in COVID-19 patients with respiratory failure.\",\"PeriodicalId\":13454,\"journal\":{\"name\":\"Immunopathologia Persa\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2023-07-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immunopathologia Persa\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.34172/ipp.2023.38457\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunopathologia Persa","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/ipp.2023.38457","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

2019年底,COVID-19在中国爆发,成为全球临床威胁。目的:本研究的目的是评估血液灌流对COVID-19合并呼吸衰竭患者的影响。患者与方法:本前瞻性研究共纳入98例18岁以上新冠肺炎聚合酶链反应(PCR)阳性患者。患者分为两组;对照组包括47名未接受血液灌流的患者,暴露组包括51名符合血液灌流标准的患者。评估所有患者的各种参数,包括全血细胞计数、血清胆红素、肌酐、c反应蛋白(CRP)和白细胞介素6 (IL-6)水平。结果:我们的研究结果显示,两组患者的重症监护病房(ICU)入院率有统计学意义。住院时间(19.941±1.75比14.615±1.39,P=0.021)、ICU时间(14.98±1.30比9.62±1.15;P=0.003)。死亡率方面,只有36.7%的患者存活;但两组间差异无统计学意义(P=0.34)。结论:综上所述,我们的研究结果表明,与未进行血液灌流的患者相比,COVID-19合并呼吸衰竭患者的住院时间和ICU住院时间明显增加。需要进一步研究确定血液灌流的最佳时机和频率,以改善COVID-19合并呼吸衰竭患者的治疗效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The effect of hemoperfusion on treatment outcomes in COVID-19 patients with respiratory failure: a prospective study
Introduction: COVID-19 emerged as a global clinical threat following an outbreak in China in late 2019. Objectives: The aim of the current study was to assess the effect of hemoperfusion in COVID-19 patients with respiratory failure. Patients and Methods: In this prospective study, a total of 98 patients over the age of 18 with the positive COVID-19 polymerase chain reaction (PCR) test were investigated. The patients were divided into two groups; a control group consisting of 47 patients who did not receive hemoperfusion, and an exposed group consisting of 51 patients who met the criteria for hemoperfusion. Various parameters including complete blood cell counts, serum bilirubin, creatinine, C-reactive protein (CRP), and interleukin 6 (IL-6) levels were evaluated in all patients. Results: The results of our study revealed a statistically significant difference in intensive care unit (ICU) admission between the two groups. Hospitalization time (19.941±1.75 versus 14.615±1.39, P=0.021) and ICU time (14.98±1.30 versus 9.62±1.15; P=0.003) were significantly higher in patients who received hemoperfusion. Regarding the mortality rate, only 36.7% of the patients survived; however, there was no significant difference observed between the two groups (P=0.34). Conclusion: In conclusion, the findings of our study indicate that hemoperfusion in COVID-19 patients with respiratory failure led to a significant increase in hospital stay and ICU stay compared to those without hemoperfusion. Further research is needed to determine the optimal timing and frequency of hemoperfusion to improve treatment outcomes in COVID-19 patients with respiratory failure.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.70
自引率
0.00%
发文量
65
审稿时长
3 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信